GlassScriptPhysician profile
Bertram Anthony Graves
NPI 1821186933
$13,972.62
in general payments reported to CMS, 2019-2025
27 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,813 · 2020: $2,300 · 2021: $1,490 · 2022: $2,353 · 2023: $1,854 · 2024: $839 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,016.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,026.88 | 2019-2025 | Farxiga, Wainua, Breztri |
| Glaxosmithkline, LLC. | $1,775.77 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $1,511.44 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $1,420.80 | 2019-2025 | |
| Amgen INC. | $1,161.73 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,039.79 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $810.49 | 2019-2023 | Mounjaro |
| Abbvie INC. | $696.63 | 2021-2023 | |
| Allergan, INC. | $520.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $332.18 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $226.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.73 | 2019-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $168.30 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $156.36 | 2022-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $124.43 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $122.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.18 | 2023 | Camzyos |
| Vifor Pharma, INC. | $109.77 | 2019-2021 | |
| Exact Sciences Corporation | $95.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Scilex Pharmaceuticals INC. | $39.92 | 2019 | |
| Janssen Biotech, INC. | $21.66 | 2019 | |
| Amryt Pharma Holdings LTD | $17.90 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.99 | 2022 | |
| Hikma Pharmaceuticals USA | $13.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bertram Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.